Darunavir / cobicistat

Phenobarbital

Contraindicated.

No pharmaceutical opinion available for this interaction.

Mechanism

Phenobarbital can induce the metabolism (CYP 3A4) and decrease the plasma concentration of Darunavir / cobicistat.

Darunavir / cobicistat

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Risk of a possible development of resistance to antiretroviral class.

Recommendations

Avoid this association or monitor for signs and symptoms of therapeutic failure.

Alternative solution(s)

Phenobarbital

Pharmacodynamic effects

Recommendations

Contraindicated. Use alternative.

Alternative solution(s)

Gabapentin, pregabalin, leviracetam.

Monitor

Tests

Viral Load

Darunavir plasma level

CD4+

Pharmacokinetic parameters

Comment

Reference
  • 3071
    Darunavir/cobicistat (Prezcobix), Janssen, Ontario, Canada, 7 avril 2017.
  • 3437
    Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), Janssen Inc, Ontario, Canada, 3 octobre 2018.